Analysts are estimating that United Therapeutics will report an earnings per share (EPS) of $6.42.
The announcement from United Therapeutics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Earnings Track Record
Last quarter the company missed EPS by $0.55, which was followed by a 4.63% increase in the share price the next day.
Here's a look at United Therapeutics's past performance and the resulting price change:
Quarter
Q2 2024
Q1 2024
Q4 2023
Q3 2023
EPS Estimate
6.40
5.65
4.19
5.08
EPS Actual
5.85
6.17
4.36
5.38
Price Change %
5.0%
1.0%
-1.0%
2.0%
Tracking United Therapeutics's Stock Performance
Shares of United Therapeutics were trading at $349.71 as of October 28. Over the last 52-week period, shares are up 56.66%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
Insights Shared by Analysts on United Therapeutics
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding United Therapeutics.
A total of 6 analyst ratings have been received for United Therapeutics, with the consensus rating being Buy. The ...